#United States #Austin #Genprex #AAV Technology #diabetes gene therapy

Genprex and Its Innovative Approach to Diabetes Gene Therapy

Genprex, Inc., a clinical-stage biotechnology company, is making strides in the field of gene therapy, particularly for diabetes management. The company’s innovative strategies will be highlighted at the upcoming Future of Cell and Gene Therapy Symposium, scheduled for November 17-18, 2026. Pier-Anne Lachance, Ph.D., Genprex's Senior Director of Quality Control and Product Development, will lead a presentation focusing on the company's dual approach to gene therapy delivery for diabetes treatment, emphasizing both viral and non-viral techniques.

Overview of the Presentation

Dr. Lachance's presentation, titled "Building the Future of Diabetes Gene Therapy Lessons from Parallel AAV and Lipid-Based Development Programs," aims to shed light on the ongoing development efforts surrounding Genprex's diabetes program. This includes the use of Adeno-Associated Virus (AAV) and a novel non-viral lipid-based delivery method. The presentation is anticipated to cover scientific, manufacturing, and developmental considerations crucial for advancing these two distinct gene delivery approaches.

The dual delivery strategy reflects a commitment to tackling challenges faced in gene therapy development. By examining both methods in a parallel manner, Genprex seeks to inform future strategies for optimizing and advancing its gene therapy initiatives.

Advancements in Diabetes Gene Therapy

Genprex focuses on developing gene therapies that restore the body’s ability to produce insulin, primarily aimed at treating both Type 1 and Type 2 diabetes. The AAV-based method intends to deliver Pdx1 and MafA genes directly to the pancreas, thereby reprogramming pancreatic cells to regain their insulin-producing function. In contrast, the lipid-based approach is designed for flexibility, offering potential advantages in treatment administration, including the possibility for repeat doses.

Both strategies are currently in preclinical stages, and their advancement signals promise for those burdened with diabetes. The two-day symposium convenes influential experts across academia and industry, setting the stage for discussions around significant advancements in cell and gene therapy, including genetic approaches for treating various diseases, the evolution of gene delivery technologies, and the scalability of manufacturing processes.

Insights from Industry Leaders

Ryan Confer, the President and CEO of Genprex, stated, "Advancing gene therapies requires not only innovative science but also a disciplined approach to delivery, manufacturing, and product development. Our commitment to evaluating both AAV-based and lipid-based approaches serves to address crucial developmental challenges as we push forward with our diabetes therapy program." This approach reinforces Genprex's dedication to incorporating comprehensive perspectives into the development pipeline, which they consider essential in navigating the complex field of gene therapies.

The upcoming symposium promises to be a fruitful occasion for knowledge exchange and collaboration, as it gathers professionals devoted to advancing cell and gene therapy innovations. Attendees will have the opportunity to learn and discuss the latest findings and methods to enhance the effectiveness of gene therapies.

About Genprex, Inc.

Founded on the principles of innovation and patient care, Genprex seeks to develop groundbreaking treatments that aim to restore biological functions impaired by illness. Aside from its diabetes gene therapy, the company is advancing its lead oncology program, REQORSA (quaratusugene ozeplasmid), which is under investigation for lung cancer treatment. Driven by a mission to translate innovative gene therapy into tangible benefits for patients, Genprex consistently strives for meaningful advancements in therapeutic strategies.

As the company prepares for the symposium, researchers, practitioners, and stakeholders alike await new insights that may lighten the burden of diabetes and move the industry towards more effective, personalized treatments for patients worldwide. For more information, visit Genprex's official site, and stay tuned for advancements following the symposium, where further details will be shared.